Demographics and clinical characteristics at T0 (time of omalizumab initiation) in minors (6–17 years) and adults (≥18 years)
| Minors | Adults | Total | |
| Subjects | 149 | 723 | 872 |
| Sex | |||
| Male | 94 (63.1) | 283 (39.1) | 377 (43.2) |
| Female | 55 (36.9) | 440 (60.9) | 495 (56.8) |
| Age at omalizumab initiation years | 11.4±3.1 | 50.8±14.2 | 44.1±19.7 |
| Weight kg | 45.6±18.1 | 75.1±16.8 | 70.0±20.3 |
| Smoking status | |||
| Nonsmoker | 142 (97.9) | 441 (64.4) | 583 (70.2) |
| Ex-smoker | 0 (0) | 180 (26.3) | 180 (21.7) |
| Current smoker | 3 (2.1) | 64 (9.3) | 67 (8.1) |
| Missing | 4 | 38 | 42 |
| Pack-years (ex-/current smoker) | 1 | 18.0±13.4 | 17.9±13.5 |
| Missing | 2 | 50 | 52 |
| Any comorbidity | 136 (91.3) | 595 (82.3) | 731 (83.8) |
| Conjunctivitis | 31 (22.8) | 85 (14.3) | 116 (15.9) |
| Nasal polyps | 0 (0) | 165 (27.7) | 165 (22.6) |
| Perennial rhinitis | 108 (79.4) | 300 (50.4) | 408 (55.8) |
| Seasonal rhinitis | 55 (40.4) | 106 (17.8) | 161 (22.0) |
| Sinusitis | 5 (3.7) | 100 (16.8) | 105 (14.4) |
| Urticaria | 5 (3.7) | 25 (4.2) | 30 (4.1) |
| Atopic dermatitis | 50 (36.8) | 40 (6.7) | 90 (12.3) |
| Food allergy | 37 (27.2) | 40 (6.7) | 77 (10.5) |
| Angio-oedema | 1 (0.7) | 2 (0.3) | 3 (0.4) |
| Anaphylaxis | 4 (2.9) | 4 (0.7) | 8 (1.1) |
| Aspirin or NSAID hypersensitivity | 0 (0) | 57 (9.6) | 57 (7.8) |
| Depression/anxiety | 7 (5.1) | 88 (14.8) | 95 (13) |
| Obesity | 12 (8.8) | 121 (20.3) | 133 (18.2) |
| GORD | 15 (11) | 169 (28.4) | 184 (25.2) |
| Asthma therapy at omalizumab initiation | |||
| ICS | 149 (100) | 708 (98.2) | 857 (98.5) |
| LABA | 123 (83.1) | 687 (95.4) | 810 (93.3) |
| OCS | 3 (2.1) | 243 (34.4) | 246 (28.9) |
| Daily dose of OCS mg·day−1 | 17.5±17.7 | 20.4±14.2 | 20.3±14.2 |
| Daily dose of ICS µg·day−1 beclomethasone equivalent | 1545±615.2 | 1990.8±1200 | 1914.7±1134 |
| Hospitalisations in prior 12 months n | 2.3±1.9 | 1.7±1.4 | 1.9±1.5 |
| Exacerbations in prior 12 months n | 5.2±3.9 | 4.3±3.1 | 4.5±3.2 |
| Total serum IgE IU·mL−1 | |||
| Mean±sd | 1361±1439 | 528.6±798 | 676±996 |
| Median (IQR) | 850.5 (353.5–1881.5) | 285 (110–602) | 345 (126–718) |
| Range | 22–8700 | 2–6900 | 2–8700 |
| Blood eosinophil count in prior 12 months cells·µL−1 | |||
| Mean±sd | 684.6±507.6 | 450.6±600.6 | 490.6±591.9 |
| Median (IQR) | 619 (280–930) | 308 (166–560) | 340 (175–622.5) |
| Range | 0–2640 | 0–8885 | 0–8885 |
Data presented as n, mean±sd or n (%), unless otherwise stated. NSAID: nonsteroidal anti-inflammatory drug; GORD: gastro-oesophageal reflux disease; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; OCS: oral corticosteroid; IQR: interquartile range.